K Number
K212738
Device Name
Amplatzer Talisman Delivery Sheath
Manufacturer
Date Cleared
2021-09-27

(28 days)

Product Code
Regulation Number
870.1250
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The Amplatzer Talisman Delivery Sheath is indicated to provide a pathway through which an Amplatzer™ PFO Occluder is introduced for patent foramen ovale closure.
Device Description
The Amplatzer Talisman Delivery Sheath is a line extension of the Amplatzer Trevisio Intravascular Delivery System. The Amplatzer Talisman Delivery Sheath is a single use sheath intended to facilitate the delivery and deployment of the Amplatzer Talisman PFO Occluder. The delivery sheath is available in 8F and 9F sizes with a 45° curve and 80 cm usable length. The sheath and dilator are radiopaque for visibility under fluoroscopy. For added visibility the sheath also has a platinum/iridium marker band near the distal tip. The Talisman Delivery Sheath is comprised of two components: a dilator to ease penetration of tissue and minimize vessel trauma, and a sheath to provide a pathway through which an Amplatzer occluder is delivered
More Information

No
The description focuses on the physical components and function of a delivery sheath, with no mention of AI or ML capabilities.

No.

A therapeutic device is one that treats, prevents, or diagnoses a disease or condition. This device is a delivery sheath, which merely facilitates the introduction of another device (the Amplatzer™ PFO Occluder) that actually performs the therapeutic action of closing the foramen ovale.

No
The device is described as a delivery sheath used to introduce an occluder for treating a patent foramen ovale, indicating a therapeutic rather than diagnostic purpose. Its role is to facilitate the delivery and deployment of another device, not to diagnose a condition.

No

The device description clearly outlines physical components (sheath, dilator, marker band) and mentions radiopacity for visibility under fluoroscopy, indicating it is a hardware device.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Device Function: The Amplatzer Talisman Delivery Sheath is a medical device used in vivo (within the body) to facilitate the delivery of another device (the Amplatzer™ PFO Occluder) for a surgical procedure. It is a tool used during an interventional procedure, not a test performed on a sample outside the body.
  • Intended Use: The intended use clearly states it provides a pathway for introducing a device for patent foramen ovale closure, which is a surgical intervention.

Therefore, the Amplatzer Talisman Delivery Sheath falls under the category of an interventional medical device, not an in vitro diagnostic.

N/A

Intended Use / Indications for Use

The Amplatzer Talisman Delivery Sheath is indicated to provide a pathway through which an Amplatzer™ PFO Occluder is introduced for patent foramen ovale closure.

Product codes

DQY

Device Description

The Amplatzer Talisman Delivery Sheath is a single use sheath intended to facilitate the delivery and deployment of the Amplatzer Talisman PFO Occluder. The delivery sheath is available in 8F and 9F sizes with a 45° curve and 80 cm usable length. The sheath and dilator are radiopaque for visibility under fluoroscopy. For added visibility the sheath also has a platinum/iridium marker band near the distal tip. The Talisman Delivery Sheath is comprised of two components: a dilator to ease penetration of tissue and minimize vessel trauma, and a sheath to provide a pathway through which an Amplatzer occluder is delivered

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

  • Biocompatibility testing: Conducted in accordance with FDA Guidance: "Use of International Standard ISO 10993-1 Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" (2020), ISO 10993-1, ISO 14971 and ASTM F2475. Testing categories included Hemocompatibility, Cytotoxicity, Sensitization, Irritation, Materials-Mediated Pyrogenicity, Acute Systemic Toxicity, and Surface Characterization. All in-vitro testing was conducted in accordance with FDA Good Laboratory Practices (GLP) Regulations, 21 CFR 58.
  • Design Verification (Bench testing, including shelf life testing): Demonstrated that the Amplatzer Talisman Delivery Sheath met all performance specifications, including Dimensional, System Leak, Handoff Force, Guidewire Compatibility, System Prep/De-air, Particulate Assessment, Sheath Integrity, Advancement Force, Recapture Force, Number of Recaptures, Luer Testing (80369), Label Indelibility & Adherence, and Shelf Life.
  • Sterilization: Provided sterile via ethylene oxide (EO) gas to achieve a Sterility Assurance Level (SAL) of 10^-6 per ISO 11135. Adopted into routine cycles used to sterilize the predicate. EO/ECH residuals assessment found acceptable per ANSI/AAMI/ISO 10993-7.
  • Packaging: Verification studies performed in compliance with ASTM F2825, ASTM D4332, ASTM F2096; F1886/F1886M and ASTM F88/F88M. All device packaging met acceptance criteria.
  • Design Validation:
    • Benchtop simulated use model: Independent physicians experienced with cardiac interventional procedures evaluated the performance of the Amplatzer Talisman Delivery Sheath to deliver the Amplatzer Talisman PFO Occluder. No observations or clinically significant comments were noted.
    • Acute animal study: Independent physicians experienced with cardiac interventional procedures evaluated one Amplatzer Talisman Delivery Sheath through simulated use of delivering an Amplatzer Talisman PFO Occluder. No observations or clinically significant comments were noted.
  • Human Factors: Evaluation performed to confirm no new user-device interactions were introduced per ANSI/AAMI/IEC 62366-1.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K190581

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 870.1250 Percutaneous catheter.

(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left side of the image is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

September 27, 2021

Abbott Medical Daniel Gapp Regulatory Affairs Project Manager 177 East County Road B St. Paul, Minnesota 55117

Re: K212738

Trade/Device Name: Amplatzer™ Talisman™ Delivery Sheath Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous catheter Regulatory Class: Class II Product Code: DQY Dated: August 27, 2021 Received: August 30, 2021

Dear Daniel Gapp:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

1

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Rachel E. Neubrander -S

Rachel Neubrander Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K212738

Device Name Amplatzer Talisman Delivery Sheath

Indications for Use (Describe)

The Amplatzer Talisman Delivery Sheath is indicated to provide a pathway through which an Amplatzer PFO Occluder is introduced for patent foramen ovale closure

Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

Image /page/3/Picture/0 description: The image shows the Abbott logo. The logo consists of a blue symbol on the left and the word "Abbott" in black on the right. The symbol is a stylized letter "a" made up of three horizontal lines connected by a vertical line on the left.

510(k) Summary

The 510(k) Summary is submitted in accordance with 21 CFR §807.92 and the requirements of the Safe Medical Device Act (SMDA) of 1990.

l. SUBMITTER INFORMATION

Submitter Name:Abbott Medical
Submitter Address:5050 Nathan Lane North
Plymouth, MN 55442
USA
Contact Person:Daniel Gapp
Phone:651 756 3329
Email:dan.gapp@abbott.com
Date Prepared:27 August 2021

DEVICE -

Name of Device:Amplatzer™ Talisman™ Delivery Sheath
Common Name:Catheter Delivery System
Classification Name:Catheter, Percutaneous (21 CFR 870.1250)
Regulatory Class:II
Product Code:DQY

lll. PREDICATE DEVICE

Predicate Device:

Amplatzer™ Trevisio™ Intravascular Delivery System (K190581, cleared on 05 April 2019)

IV. DEVICE DESCRIPTION

The Amplatzer Talisman Delivery Sheath is a line extension of the Amplatzer Trevisio Intravascular Delivery System. The Amplatzer Talisman Delivery Sheath is a single use sheath intended to facilitate the delivery and deployment of the Amplatzer Talisman PFO Occluder. The delivery sheath is available in 8F and 9F sizes with a 45° curve and 80 cm usable length. The sheath and dilator are radiopaque for visibility under fluoroscopy. For added visibility the sheath also has a platinum/iridium marker band near the distal tip. The Talisman Delivery Sheath is comprised of two components: a dilator to ease penetration of tissue and minimize vessel trauma, and a sheath to provide a pathway through which an Amplatzer occluder is delivered

V. INDICATION FOR USE

The Amplatzer Talisman Delivery Sheath is indicated to provide a pathway through which an Amplatzer™ PFO Occluder is introduced for patent foramen ovale closure.

COMPARISON OF TECHNOLOGICAL CHARACTERISTICS VI.

4

Image /page/4/Picture/0 description: The image shows the logo for Abbott. The logo consists of a blue square with a stylized "a" inside, followed by the word "Abbott" in black, bold font. The logo is simple and modern, and the colors are eye-catching.

The Amplatzer Talisman Delivery Sheath incorporated substantially equivalent design, function, packaging, sterilization process, materials, fundamental technology, indication for use, intended use and operating principles as those shared by the primary predicate device, the Amplatzer Trevisio Intravascular Delivery System (K190581).

A comparison of the Amplatzer Talisman Delivery Sheath and the Amplatzer Trevisio Intravascular Delivery System Trevisio™ Intravascular Delivery System shows that these devices have identical characteristics, including the sheath and dilator.

SUMMARY OF NON-CLINICAL PERFORMANCE TESTING VII.

The following design verification and validation testing was provided in support of a substantial equivalence determination.

Biocompatibility testing:

The biocompatibility evaluation of the Amplatzer Talisman Delivery Sheath was conducted in accordance with the FDA Guidance: Use of International Standard ISO 10993-1 Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" (2020), ISO 10993-1, ISO 14971 and ASTM F2475. Testing was conducted in the following categories:

  • Hemocompatibility ●
  • Cytotoxicity ●
  • Sensitization ●
  • Irritation
  • Materials-Mediated Pyrogenicity ●
  • . Acute Systemic Toxicity
  • Surface Characterization

The Amplatzer Talisman Delivery Sheath is considered an external communicating device with limited (≤24 hour) contact with circulating blood. All in-vitro testing was conducted in accordance with FDA Good Laboratory Practices (GLP) Requlations, 21 CFR 58.

Design Verification

Bench testing, including shelf life testing, was conducted to demonstrate that the Amplatzer Talisman Delivery Sheath met all performance specifications, including:

  • Dimensional ●
  • System Leak ●
  • Handoff Force ●
  • Guidewire Compatibility ●
  • System Prep/De-air ●
  • . Particulate Assessment
  • Sheath Integrity
  • Advancement Force ●
  • Recapture Force ●
  • Number of Recaptures ●
  • Luer Testing (80369) ●
  • Label Indelibility & Adherence ●
  • Shelf Life ●

Sterilization

The Amplatzer Talisman Delivery Sheath is intended for single use only and is provided sterile via ethylene oxide (EO) gas to achieve a Sterility Assurance Level (SAL) of 10® per ISO 11135. The Amplatzer Talisman Delivery Sheath was adopted into routine cycles

5

Image /page/5/Picture/0 description: The image shows the Abbott logo. The logo consists of a blue abstract shape on the left and the word "Abbott" in black on the right. The abstract shape is a stylized letter "a" with a rounded corner. The word "Abbott" is in a bold, sans-serif font.

used to sterilize the primary predicate device, the Trevisio Delivery System, based on a comparison of composition, packaging, design, pallet density, and bioburden levels per ANSI/AAMI TIR 28. An EO/ECH residuals assessment found the residuals to be acceptable with respect to the predicate device per ANSI/AAMI/ISO 10993-7, following 2X sterilization.

Packaging

Packaging verification studies were performed in compliance with the applicable requirements of ASTM F2825, ASTM D4332, ASTM F2096; F1886/F1886M and ASTM F88/F88M. All device packaging evaluated met acceptance criteria following 2X sterilization, environmental conditioning and transport simulation.

Design Validation

Two design validation studies were performed to evaluate the Amplatzer Talisman Delivery Sheath to deliver an Amplatzer Talisman PFO Occluder. In a benchtop simulated use model, independent physicians experienced with cardiac interventional procedures evaluated the performance of the Amplatzer Talisman Delivery Sheath to deliver the Amplatzer Talisman PFO Occluder. There were no observations or clinically significant comments noted by the physician evaluators during this design validation study.

Additionally, an acute animal study was also conducted to evaluate the performance of the Amplatzer Talisman Delivery Sheath to deliver an Amplatzer Talisman PFO Occluder. Independent physicians experienced with cardiac interventional procedures evaluated one Amplatzer Talisman Delivery Sheath through simulated use of delivering an Amplatzer Talisman PFO Occluder. There were no observations or clinically significant comments noted by either of the two physician evaluators during this design validation study.

Human Factors

A Human Factors evaluation of the Amplatzer Talisman Delivery Sheath was performed to confirm no new user-device interactions were introduced per the requirements of ANSI/AAMI/IEC 62366-1.

VIII CONCLUSION

Abbott Medical considers the Amplatzer Talisman Delivery Sheath to be substantially equivalent to the Amplatzer Trevisio Intravascular Delivery System. This conclusion is based upon the devices' similarities in principles of operation, technology, materials and indications for use.